Acadia Pharmaceuticals Q1 2023 Earnings Call Presentation

Acadia Pharmaceuticals' first quarter 2023 earnings presentation covers commercial updates on NUPLAZID and DAYBUE, R&D progress, and financial performance. The company discusses forward-looking plans for product commercialization, clinical development, and market expansion in neurological and psychiatric indications including Parkinson's disease psychosis, schizophrenia, and Rett syndrome.